Pharmaceuticals News 3 October 2025

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market.

16 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On

16 October 2025

Biotech · Company Analysis · Investing · NASDAQ:ADAP · NASDAQ:HTGC · Pharmaceuticals · Stock Market

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Figure: Hims & Hers markets a broad telehealth platform for men’s and women’s health ts2.tech. Its stock has surged with the boom in telehealth and weight-loss treatments. Women’s Health Expansion Sparks Rally On Oct. 15, Hims & Hers stunned the

16 October 2025

Health · Investments · Menopause · NASDAQ:HIMS · Pharmaceuticals · Stock Market

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 investing.com. Notably, on Sept. 30 ABBV hit a 52-week

11 October 2025

Biotech · Financial Analysis · Investing · NYSE:ABBV · Pharmaceuticals · Stock Market

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicines marketbeat.com astrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR

11 October 2025

Analyst Insights · Business News · Investment · Pharmaceuticals · Stock Market

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Metric Merck (MRK) Last Price (10/10/25) $86.02 marketbeat.com Market Cap $215B marketbeat.com P/E (TTM) ~13× marketbeat.com Yield 3.8% marketbeat.com 52-Week Range $73.31 – $111.58 marketbeat.com YTD Total Return -11.07% financecharts.com Q2 2025 Sales $15.8B investing.com 2024 Sales $64.2B merck.com 2024 R&D

11 October 2025

Drug Approvals · Financial News · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche

11 October 2025

Biotech · Clinical Trials · Mergers & Acquisitions · Pharmaceuticals · Stock Market

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approved reuters.com. By then, the landscape

9 October 2025

Drug Development · Healthcare Industry · Liver Health · Medical Innovation · NASDAQ:AKRO · NYSE:NVO · Pharmaceuticals

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Current News & October 2025 Updates EMA Positive Opinion: A major recent catalyst for Acurx came on September 30, 2025, when the EMA’s Paediatric Committee issued a positive opinion on the Pediatric Investigation Plan (PIP) for Acurx’s lead drug, ibezapolstat, in Clostridioides difficile infection investing.com. This essentially

8 October 2025

Analyst Predictions · Investment Insights · Market Trends · NASDAQ:ACXP · Pharmaceuticals · Stock Analysis

Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Puerto Rico’s pharmaceutical roots and the Section 936 story For much of the late 20th century, Puerto Rico was an unlikely but critical component of America’s medicine chest. The island’s status as a U.S. territory provided access to federal intellectual‑property protections, Food

6 October 2025

Business Opportunities · Manufacturing · Pharmaceuticals · Puerto Rico Economy · Reshoring

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 %

4 October 2025

Biotech · Investment Analysis · Market Trends · NASDAQ:CDTX · Pharmaceuticals · Stock Market · Stocks

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis (eyelid inflammation caused by Demodex mites) globenewswire.com. Tarsus

3 October 2025

Biotechnology · Healthcare · Investment News · NASDAQ:TARS · Pharmaceuticals · Stock Market

Pharmaceuticals News 3 October 2025 - 16 October 2025